Atara Biotherapeutics
ATRA
120 hedge funds and large institutions have $1.94B invested in Atara Biotherapeutics in 2019 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 16 closing their positions.
250% more call options, than puts
Call options by funds: $7.58M | Put options by funds: $2.16M
37% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 38
16% more capital invested
Capital invested by funds: $1.68B → $1.94B (+$264M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more ownership
Funds ownership: 4.23% → 4.23% (+0%)
1% less funds holding
Funds holding: 121 → 120 (-1)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.5M |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
+$32.4M |
| 3 |
JP Morgan Chase
New York
|
+$24.9M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$20.4M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.8M |
Top Sellers
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$53.5M |
| 2 |
Morgan Stanley
New York
|
-$20.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.2M |
| 4 |
BM
Bridger Management
New York
|
-$16.9M |
| 5 |
HCM
Highline Capital Management
New York
|
-$8.96M |
ATRA Hedge Fund Activity: Q1 2019 in Review
120 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2019, worth a combined $1.94B — up 16% from $1.68B a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ATRA and 15 opened new positions — a net loss of 1 holder — while 38 trimmed existing stakes and 52 added.
The largest buyer was Fidelity Investments, adding an estimated $42.5M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $53.5M.
- 120 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2019, down from 121 in Q4 2018.
- Funds reported $1.94B of Atara Biotherapeutics stock for Q1 2019, up 16% quarter-over-quarter.
- 15 funds opened new Atara Biotherapeutics positions in Q1 2019 and 16 closed out, a net change of -1 holder.
- The largest Atara Biotherapeutics buyer in Q1 2019 was Fidelity Investments, an estimated $42.5M added.
- The largest Atara Biotherapeutics seller in Q1 2019 was ArrowMark Colorado Holdings, an estimated $53.5M sold.
Based on aggregated 13F filings for Q1 2019.